GT201700184A - Nuevas proteínas específicas para pioverdina y pioquelina - Google Patents

Nuevas proteínas específicas para pioverdina y pioquelina

Info

Publication number
GT201700184A
GT201700184A GT201700184A GT201700184A GT201700184A GT 201700184 A GT201700184 A GT 201700184A GT 201700184 A GT201700184 A GT 201700184A GT 201700184 A GT201700184 A GT 201700184A GT 201700184 A GT201700184 A GT 201700184A
Authority
GT
Guatemala
Prior art keywords
muteines
pioverdina
pioquelina
specific proteins
description
Prior art date
Application number
GT201700184A
Other languages
English (en)
Inventor
Carsten Corvey
Heike Stump
Jochen Kruip
Astrid Rey
Nathalie Karst
Michael Mourez
Laurent Fraisse
Christine Rothe
Andrea Allersdorfer
Alexander Wiedenmann
Marlon Hinner
Bradley Lunde
Kristian Jensen
Martin Hülsmeyer
Calandra Bernard
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of GT201700184A publication Critical patent/GT201700184A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

LA PRESENTE DESCRIPCIÓN PROPORCIONA MUTEÍNAS DE HNGAL QUE SE UNEN CON UN MIEMBRO DE LA FAMILIA DE PIOVERDINA O PIOQUELINA Y QUE PUEDEN USARSE EN DIVERSAS APLICACIONES INCLUYENDO APLICACIONES FARMACÉUTICAS, POR EJEMPLO, PARA INHIBIR O REDUCIR EL CRECIMIENTO DE P. AERUGINOSA. LA PRESENTE DESCRIPCIÓN TAMBIÉN SE REFIERE A MÉTODOS PARA PREPARAR UNA O MÁS MUTEÍNAS DE UNIÓN A PIOVERDINA O A PIOQUELINA DESCRITAS EN LA PRESENTE MEMORIA ASÍ COMO A COMPOSICIONES QUE COMPRENDEN UNA O MÁS DE DICHAS MUTEÍNAS. LA PRESENTE DESCRIPCIÓN SE REFIERE ADEMÁS A MOLÉCULAS DE ÁCIDO NUCLEICO QUE CODIFICAN DICHAS MUTEÍNAS Y A MÉTODOS PARA LA GENERACIÓN DE DICHAS MUTEÍNAS Y MOLÉCULAS DE ÁCIDO NUCLEICO. ADEMÁS, LA SOLICITUD DESCRIBE USOS TERAPÉUTICOS Y/O DE DIAGNÓSTICO DE ESTAS MUTEÍNAS ASÍ COMO COMPOSICIONES QUE COMPRENDEN UNA O MÁS DE DICHAS MUTEÍNAS.
GT201700184A 2015-02-18 2017-08-17 Nuevas proteínas específicas para pioverdina y pioquelina GT201700184A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15305242 2015-02-18

Publications (1)

Publication Number Publication Date
GT201700184A true GT201700184A (es) 2018-10-24

Family

ID=52595246

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201700184A GT201700184A (es) 2015-02-18 2017-08-17 Nuevas proteínas específicas para pioverdina y pioquelina

Country Status (28)

Country Link
US (8) US9884898B2 (es)
EP (1) EP3259282A1 (es)
JP (1) JP6843754B2 (es)
KR (1) KR20170116158A (es)
CN (1) CN107660211A (es)
AR (1) AR103714A1 (es)
AU (1) AU2016221816B2 (es)
BR (1) BR112017017530A2 (es)
CA (1) CA2976687A1 (es)
CL (1) CL2017002082A1 (es)
CO (1) CO2017009433A2 (es)
CR (1) CR20170425A (es)
DO (1) DOP2017000191A (es)
EA (1) EA035824B1 (es)
EC (1) ECSP17061751A (es)
GT (1) GT201700184A (es)
HK (1) HK1245293A1 (es)
IL (1) IL254013A0 (es)
MA (1) MA41072A1 (es)
MX (1) MX375049B (es)
PE (1) PE20171652A1 (es)
PH (1) PH12017501473A1 (es)
SG (1) SG11201706621SA (es)
TN (1) TN2017000348A1 (es)
TW (1) TW201636364A (es)
UY (1) UY36561A (es)
WO (1) WO2016131804A1 (es)
ZA (1) ZA201705257B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2510357B1 (en) 2009-12-07 2016-03-30 Pieris AG Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
CA2949405C (en) 2014-05-22 2023-08-01 Pieris Pharmaceuticals Gmbh Novel specific-binding polypeptides and uses thereof
RU2720688C2 (ru) 2015-01-28 2020-05-12 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Новые белки, специфические в отношении ангиогенеза
AU2016221816B2 (en) * 2015-02-18 2020-07-02 Pieris Pharmaceuticals Gmbh Novel proteins specific for pyoverdine and pyochelin
AU2016258977C1 (en) 2015-05-04 2022-07-14 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
AU2016258952C1 (en) 2015-05-04 2020-12-24 Pieris Pharmaceuticals Gmbh Proteins specific for CD137
RU2754466C2 (ru) 2015-05-18 2021-09-02 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Слитый полипептид с противораковой активностью
US10273275B2 (en) 2015-05-18 2019-04-30 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) and methods of use thereof
EP3115371A1 (en) * 2015-07-07 2017-01-11 Sanofi Fusion molecules
CN108699162A (zh) 2015-11-30 2018-10-23 皮里斯澳大利亚有限公司 新型抗血管生成融合多肽
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
WO2018087108A1 (en) * 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
EP3823667A4 (en) * 2018-07-19 2022-07-27 The Regents Of The University Of Colorado Methods, systems and compositions for the novel use of enterobactin to treat iron deficiency and related anemia
US20220168387A1 (en) 2019-03-29 2022-06-02 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins
CN116077621B (zh) * 2021-11-05 2026-03-24 华南农业大学 P19蛋白在调控绿脓杆菌毒力中的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
CN1170543C (zh) 1998-06-08 2004-10-13 弗·哈夫曼-拉罗切有限公司 PEG-IFN-α和三唑核苷在治疗慢性丙型肝炎中的用途
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
JP4469456B2 (ja) * 2000-04-19 2010-05-26 第一三共株式会社 緑膿菌鉄獲得系阻害物質のスクリーニング法
EP1377306A1 (en) 2001-03-09 2004-01-07 Dyax Corp. Serum albumin binding moieties
US7056702B2 (en) * 2002-12-16 2006-06-06 Kimberly Clark Co Detecting lipocalin
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
WO2007038619A2 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
EP3381933B1 (en) 2008-06-24 2020-06-03 Technische Universität München Muteins of hngal and related proteins with affinity for a given target
WO2011149962A1 (en) * 2010-05-24 2011-12-01 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
US10526384B2 (en) 2012-11-19 2020-01-07 Pieris Pharmaceuticals Gmbh Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof
CN103074303A (zh) * 2012-12-27 2013-05-01 中国人民解放军第三军医大学 产生抗人ngal特异性单克隆抗体的杂交瘤细胞株及其产生的单克隆抗体与应用
AU2016221816B2 (en) * 2015-02-18 2020-07-02 Pieris Pharmaceuticals Gmbh Novel proteins specific for pyoverdine and pyochelin
EP3115371A1 (en) 2015-07-07 2017-01-11 Sanofi Fusion molecules

Also Published As

Publication number Publication date
US20180346532A1 (en) 2018-12-06
US20180037619A1 (en) 2018-02-08
US20180086799A1 (en) 2018-03-29
TW201636364A (zh) 2016-10-16
BR112017017530A2 (pt) 2018-04-17
UY36561A (es) 2016-09-30
US10118952B2 (en) 2018-11-06
US20180037618A1 (en) 2018-02-08
CL2017002082A1 (es) 2018-04-27
US10065998B2 (en) 2018-09-04
AR103714A1 (es) 2017-05-31
CN107660211A (zh) 2018-02-02
US10329334B2 (en) 2019-06-25
US20170267734A1 (en) 2017-09-21
EA035824B1 (ru) 2020-08-17
DOP2017000191A (es) 2017-09-29
US10072056B2 (en) 2018-09-11
AU2016221816A1 (en) 2017-10-12
CR20170425A (es) 2017-11-22
US20180371038A1 (en) 2018-12-27
US9884898B2 (en) 2018-02-06
MX2017010628A (es) 2017-12-07
MX375049B (es) 2025-03-06
ZA201705257B (en) 2019-06-26
AU2016221816B2 (en) 2020-07-02
JP6843754B2 (ja) 2021-03-17
PH12017501473A1 (en) 2018-01-29
MA41072A1 (fr) 2018-10-31
CO2017009433A2 (es) 2017-11-30
WO2016131804A1 (en) 2016-08-25
US20180371037A1 (en) 2018-12-27
PE20171652A1 (es) 2017-11-13
SG11201706621SA (en) 2017-09-28
HK1245293A1 (zh) 2018-08-24
JP2018506979A (ja) 2018-03-15
US20180030101A1 (en) 2018-02-01
EA201791841A1 (ru) 2018-01-31
EP3259282A1 (en) 2017-12-27
IL254013A0 (en) 2017-10-31
TN2017000348A1 (en) 2019-01-16
ECSP17061751A (es) 2017-10-31
KR20170116158A (ko) 2017-10-18
CA2976687A1 (en) 2016-08-25

Similar Documents

Publication Publication Date Title
DOP2017000191A (es) Nuevas proteínas específicas para pioverdina y pioquelina
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
CU20170172A7 (es) 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
NI201600071A (es) Compuestos de inhibidor de autotaxina
PY1520796A (es) Composiciones plaguicidas y metodos relacionados
CR20160222U (es) Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas
BR112016027871A2 (pt) composição para melhorar a memória, a função de aprendizado e/ou função cognitiva
MX385926B (es) Proteínas de fusión de citoquinas.
MX389847B (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
MX2015015409A (es) Proceso para la preparacion de eritrocitos cargados con una o mas sustancias de interes farmaceutico y eritrocitos asi obtenidos.
MX381776B (es) Formulacion acuosa que comprende paracetamol e ibuprofeno.
AR112069A1 (es) Inmunoglobulinas que fijan aggrecan
CO2017004735A2 (es) Moléculas que tienen utilidad plaguicida e intermediarios, composiciones y procedimientos relacionados con las mismas
UY36157A (es) Composiciones pesticidas y procedimientos relacionados con las mismas
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
BR112018004310A2 (pt) derivados de espinosina e método de preparação
MX2017000676A (es) Oritavancina de alta pureza y metodo para producir la misma.
MX2018002514A (es) Citotoxinas modificadas y su uso terapeutico.
BR112015030135A2 (pt) ésteres de ácidos oligo-hidróxi carboxílicos e seu uso
BR112017016388A2 (pt) cenicriviroc para o tratamento da fibrose
AR105257A1 (es) Moléculas de fusión que tiene especificidad de unión a pioverdina y pioquelina
MX389461B (es) Composiciones que comprenden una matriz de polisacarido para la liberacion controlada de ingredientes activos